Silvergate Capital CEO Alan Lane to Exit as Crypto Bank Winds Down
By Will Feuer
Silvergate Capital Chief Executive Alan Lane and other executives are leaving the company amid the wind down and liquidation of Silvergate Bank.
Lane and Chief Legal Officer John Bonino will both leave, effective Tuesday. Chief Financial Officer Antonio Martino will exit, effective Sept. 30. The company said in a securities filing that it doesn't expect to name another CEO or CFO as it seeks to liquidate Silvergate Bank.
Kathleen Fraher, the company's current chief transition officer, will serve as principal executive officer, effective following Lane's departure.
Andrew Surry, chief accounting officer of Silvergate Bank, will serve as the company's principal financial officer following the departure of Martino.
Silvergate, which focused on companies in the crypto industry, said earlier this year it would wind down and return all deposits following a run that forced it to sell off assets at a steep loss to cover billions of dollars of withdrawals.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
August 15, 2023 18:29 ET (22:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track